Library

АЛЕФ-6

ALEPH-6 is an extremely rare research chemical from Alexander Shulgin's PiHKAL with minimal human data. At 40mg oral, Shulgin described it as producing only threshold effects that were 'hopelessly compromised,' and no higher doses were explored. The compound was considered a disappointment with uncertain activity. Due to structural similarity to active ALEPH compounds and DOx psychedelics, extreme caution is warranted. The compound may have unpredictable effects and weak MAO-A inhibitory properties.

Classification

  • Chemical: Amphetamine
  • Chemical: Phenethylamine
  • Psychoactive: Psychedelic
  • Psychoactive: Stimulant
  • Tag: Research-Chemical

Effects

  • Stimulation
  • Physical Discomfort
  • Fatigue
  • Insomnia
  • Increased Heart Rate
  • Pupil Dilation
  • Threshold Psychedelic Effects
  • Cognitive Changes
  • Talkativeness
  • Alertness Enhancement
  • Euphoria
  • Anxiety
  • Visual Alterations
  • Bodily Sensations
  • Light Sensitivity
  • Color Enhancement
  • Open Eye Visuals
  • Tactile Enhancement

Routes of Administration

Oral

Dosage

  • Threshold: ≥40 mg likely threshold (30 mg gave only +1)

Duration

  • Onset: 1-3 h
  • Peak: 3-6 h
  • Offset: 8-20 h
  • After Effects: 20-30 h
  • Total Duration: 12-20 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu

ALEPH-6 - Даведнік па рэчыве DrugsPRO

ALEPH-6: ALEPH-6 is an extremely rare research chemical from Alexander Shulgin's PiHKAL with minimal human data. At 40mg oral, Shulgin described it as producing only threshold effects that were 'hopelessly compromised,' and no higher doses were explored. The compound was considered a disappointment

Related pages